PET points to neuroinflammation in chronic fatigue syndrome
The symptoms experienced by those who suffer from chronic fatigue may be related to acute inflammation in the brain, according to a PET study published March 24 in the Journal of Nuclear Medicine . {read more here}
Japanese researchers are using PET to visualize copper distribution in mice to potentially identify therapies for a genetic disorder known as Menkes disease. The study, led by Dr. Shiho Nomura of Osaka City University and published online March 13 in the Journal of Nuclear Medicine, could lay the groundwork for PET studies of human Menkes patients to identify new therapy options. {read more here}
18F-FDG PET/CT performs better than CT/MRI in depicting occult cervical metastatic nodes in patients with negative neck palpitation findings (stage cN0), according to a study published in the April issue of Radiology. {read more here}
F-18 florbetaben, also known as Neuraceq, received U.S. Food and Drug Administration (FDA) approval today as a diagnostic amyloid agent to help rule out Alzheimer’s disease. The news comes on the heels of the agent’s European Commission green light a month ago to market the drug in Europe. The PET agent is used to approximate the density of amyloid plaque in the brain for cognitively impaired patients suspected to be developing Alzheimer’s disease and other neurodegenerative disorders.{read more here}